Eravacycline combination for resistant pneumonia
Part of Infections, Lungs & breathing clinical trials.
This study tests a combination treatment using eravacycline, an antibiotic, for pneumonia caused by bacteria that are resistant to many other antibiotics. It aims to see if this treatment can help patients who have not responded to standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have pneumonia symptoms and imaging results that suggest a bacterial infection.
- You have tested positive for Acinetobacter baumannii bacteria that are resistant to carbapenem antibiotics, in at least two sputum samples, with one from a deep airway sample.
- You have been taking eravacycline for at least 3 days.
- You are willing to participate and sign a consent form, or have a legal guardian do so.
- You do not have a history of allergy to tetracycline antibiotics.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the antibiotic eravacycline works in seriously ill patients who have not improved with other antibiotics. It aims to understand how the drug behaves in the body to help guide dosing and improve treatment.
This trial compares different treatment options for patients in the ICU who have a resistant bacterial infection called Acinetobacter baumannii. If you have this infection after surgery, the study aims to find the best way to treat it.
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
This trial is checking how well a combination of two antibiotics, aztreonam and avibactam, works in patients who have a specific type of drug-resistant bacterial infection in the belly or lungs. It aims to offer a new treatment option for infections that are hard to cure.
This Phase 2 study tests whether taking Xerava (an antibiotic) can prevent serious infections in people who have prolonged low neutrophils after chemotherapy or transplant preparation. If it works, it may lower the risk of infections during the highest-risk period after treatment.
Hear when a new Pneumonitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.